GlaxoSmithKline PLC Ownership
| GSK Stock | USD 35.36 0.30 0.86% |
GlaxoSmithKline |
GlaxoSmithKline Stock Ownership Analysis
About 15.0% of the company shares are owned by institutional investors. The book value of GlaxoSmithKline PLC was currently reported as 3.43. The company has Price/Earnings To Growth (PEG) ratio of 0.81. GlaxoSmithKline PLC ADR last dividend was issued on the 15th of November 2024. The entity had 1226:1000 split on the 22nd of July 2022. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Gsk Plc is traded on New York Stock Exchange in the United States. To learn more about GlaxoSmithKline PLC ADR call Emma Walmsley at 44 20 8047 5000 or check out https://www.gsk.com.GlaxoSmithKline PLC's latest congressional trading
Congressional trading in companies like GlaxoSmithKline PLC ADR, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in GlaxoSmithKline PLC by those in governmental positions are based on the same information available to the general public.
| 2024-11-28 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
| 2024-11-27 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
| 2023-11-16 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-11-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify |
GlaxoSmithKline PLC Outstanding Bonds
GlaxoSmithKline PLC issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlaxoSmithKline PLC ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlaxoSmithKline bonds can be classified according to their maturity, which is the date when GlaxoSmithKline PLC ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US377320AA45 Corp BondUS377320AA45 | View | |
| GLAXOSMITHKLINE CAPITAL PLC Corp BondUS377373AH85 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AM97 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AN70 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AB33 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AJ68 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AE71 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.